Skip to main content
  • Circulating Tumor Cells in Patients with Glioblastoma

    Final Number:

    Brian V. Nahed MD; James P Sullivan Ph.D.; Marissa W Madden B.S.; Samantha M Oliveira B.S.; Andrew S Chi MD; Simeon Springer; Hiro Wakimoto MD; Deepak Bhere Ph.D.; Ajay Shah Ph.D.; Phil Spuhler B.S.; Tracy Batchelor MD; David N. Louis MD; Mehmet Toner Ph.D.; Shyamala Maheswaran Ph.D.; Daniel A Haber M.D. Ph.D.

    Study Design:
    Laboratory Investigation

    Subject Category:

    Meeting: Congress of Neurological Surgeons 2014 Annual Meeting

    Introduction: Glioblastoma (GBM) is characterized by necrosis, angiogenesis, and inevitable recurrence. Despite it’s aggressiveness, GBM rarely form extra-cranial metastases suggesting impediments in vascular invasion, survival in circulation or implantation. Advances in microfluidics have successfully identified circulating tumor cells (CTCs) in lung, prostate, and breast cancer patients. Using a novel CTC microfluidic device, we hypothesize that GBM patients have CTCs, which can be captured, quantified, and analyzed for molecular and genetic markers.

    Methods: We developed a microfluidic device (CTC-iChip) capable of capturing CTCs from whole blood via immunomagnetic depletion of hematopoietic blood cells. Using GBM-specific antibodies, we validated our CTC-iChip using GBM cell lines spiked into healthy donor blood. After successfully establishing our device, we evaluated venous blood samples (10 ml) from 6 healthy donors and 33 GBM patients preoperatively and postoperatively including chemotherapy and radiation therapy. CTCs were stained with a cocktail of GBM-specific antibodies and scanned by automated fluorescence microscopy. CTCs and their matched pathological specimens from surgery were further analyzed by Fluorescence in-Situ Hybridization (FISH).

    Results: CTCs were detectable in at least one blood sample in 14/33 (42%) GBM patients. Patients with progressive disease harbored a median 11.8 CTCs per ml (mean 13.6 ± 10.7) compared to 2.1 CTCs per ml (mean: 4.0 ± 2.7) in patients with stable disease. CTC detection was significantly associated with disease progression (p-value: 0.03), but not with other clinical variables such as disease location, extent of resection, or genotype. FISH analysis of CTCs from EGFR-amplified and Chr7-polysomy GBM patients revealed 30/36 (83.3%) CTCs harbored concordant molecular aberrations.

    Conclusions: We identify the first evidence of CTCs in the peripheral blood of GBM patients. CTC frequency often varies during the course of therapy and is correlated with disease progression. Further studies are needed to define this novel discovery and its potential role in the care of GBM patients.

    Patient Care: Our study is the first to identify circulating tumor cells (CTCs) in peripheral blood of patients with glioblastoma. This novel finding has the potential to provide clinicians and their patients with a blood-based test for diagnosis, and detection of response to treatment, and mutational changes from treatment. We demonstrate that CTCs, when present, were associated with disease progression; this may prove useful in distinguishing tumor recurrence from treatment effect which is a limitation of current imaging techniques. Further investigation is required to define the role CTC analysis will play in the care of GBM patients.

    Learning Objectives: 1) Evaluate the role of blood based tests in the detection of glioblastoma 2) Evaluate the potential for circulating tumor cells to provide information about a patient's disease status


We use cookies to improve the performance of our site, to analyze the traffic to our site, and to personalize your experience of the site. You can control cookies through your browser settings. Please find more information on the cookies used on our site. Privacy Policy